About: DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19
Creator	Cracowski, Jean-Luc Auffret, Marine Cornu, Catherine Cucherat, Michel Grenet, Guillaume Gueyffier, François Lega, Jean-Christophe Mainbourg, Sabine Mekhaldi, Samia Pharmd, Mekhaldi
Source	MedRxiv
abstract	Background Association between DPP4 inhibitors and respiratory infection remains unclear. CardioVascular Outcomes Trials (CVOTs) conducted before the COVID-19 pandemic are available. We aimed to estimate the effect of DPP4 inhibitors on the risk of respiratory infections. Methods We updated a previous systematic review and meta-analysis, searching for CVOTs assessing a DPP4 inhibitor in patients with type 2 diabetes mellitus. We focused on placebo-controlled CVOTs. Our primary outcome was 'any respiratory infection'. We added a sensitivity analysis integrating non-CVOTs and active-controlled CVOTs. Findings We included 47 714 patients in five placebo-controlled CVOTs. Median follow-up ranged from 1.5 years to 3 years. 4 369 events of overall respiratory infection were reported (rate of 9.2%). DPP4 inhibitors were not associated with a different risk compared to placebo (RR = 0.99 [95%CI: 0.93; 1.04]). The sensitivity analysis integrating the non-CVOTs studies and the active-controlled CVOT reached 11 349 events among 82 644 participants (rate of 13.7%). DPP4 inhibitors were not associated with a different risk of overall respiratory infection (RR = 1.00 [95% CI: 0.97; 1.03]). Interpretation Our up-dated meta-analysis provides the most powerful and least biased estimation of the association of DPP4 inhibitors and the risk of overall (non COVID-19) respiratory infection. We did not find any effect of the DPP4 inhibitors on the risk of respiratory infection. Our results support the recently published practical recommendations for the management of diabetes in patients with COVID-19, suggesting that DPP4 inhibitors should not be discontinued regarding the COVID-19 pandemic.
has issue date	2020-07-29(xsd:dateTime)
bibo:doi	10.1101/2020.07.28.20163386
has license	medrxiv
sha1sum (hex)	a9f9f5fc1a2c1decd5f1c135e177ec552dc04a4d
schema:url	https://doi.org/10.1101/2020.07.28.20163386
resource representing a document's title	DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19
resource representing a document's body	covid:a9f9f5fc1a2c1decd5f1c135e177ec552dc04a4d#body_text
is schema:about of	named entity 'PHARMACOVIGILANCE' named entity 'DPP4' named entity 'inhibitors' named entity 'systematic review' named entity 'DPP4' named entity 'systematic review' named entity 'COVID' named entity 'respiratory infection' named entity 'infection' named entity 'adverse effect' named entity 'respiratory infection' named entity 'Systematic Reviews' named entity 'sensitivity analysis' named entity 'treatment effect' named entity 'body mass index' named entity 'diabetes' named entity 'France' named entity 'DPP4' named entity 'diabetes' named entity 'placebo-controlled' named entity 'small study' named entity 'meta-analysis' named entity 'DPP4' named entity 'COVID-19 pandemic' named entity 'Randomized trials' named entity 'pharmacovigilance' named entity 'funnel plot' named entity 'pneumonia' named entity 'COVID-19' named entity 'COVID-19' named entity 'July 29' named entity 'assessing risk' named entity 'respiratory infection' named entity 'causality' named entity 'type 2 diabetes mellitus' named entity 'randomized trials' named entity 'acute respiratory infections' named entity 'diabetes' named entity '4.11' named entity 'diabetes' named entity 'randomized controlled trial' named entity 'antihypertensive drugs' named entity 'respiratory infections' named entity 'type 2 diabetes' named entity 'sensitivity analysis' named entity 'follow-up' named entity 'sample size' named entity 'PROSPERO' named entity 'respiratory infection' named entity 'DPP4' named entity 'pregnant women' named entity 'heterogeneity' named entity 'agonist' named entity 'CC-BY-ND' named entity 'SGLT2' named entity 'Publication bias' named entity 'sitagliptin' named entity 'placebo controlled trials' named entity 'DPP4 inhibitor' named entity 'DPP4' named entity 'COVID-19' named entity 'DPP4' named entity 'Systematic Reviews' named entity 'respiratory infection' named entity 'gliptin' named entity 'treatment effect' named entity 'COVID-19 pandemic' named entity 'meta-analysis' named entity 'metaanalysis' named entity 'placebo' named entity 'enzyme' named entity 'DPP4' named entity 'medRxiv' named entity 'placebo-controlled' named entity 'sample size' named entity 'interquartile range'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software